58results about How to "Decreased substances" patented technology

The present invention provides improved devices and methods for inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled substance delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. The luminal delivery prosthesis comprises a scaffold which is implantable within a body lumen and means on the scaffold for releasing a substance from the scaffold. The substance is released over a predetermined time pattern comprising an initial phase wherein the substance delivery rate is below a threshold level and a subsequent phase wherein the substance delivery rate is above a threshold level.

The transfer type inkjet recording method has the intermediate image formation process and the transfer process defined in the specification. The transfer type inkjet recording method includes, in the intermediate image formation process, selecting an intermediate transfer body having a center line surface roughness closest to the center line surface roughness of a recording medium from a plurality of intermediate transfer bodies different from each other in the center line surface roughness, and then an intermediate image is formed on the surface of the selected intermediate transfer body. Moreover, a transfer type inkjet recording which is used for the method is provided.

This invention relates to a chemically modified hyaluronic acid and salts thereof, which are obtained by O-acylating, alkoxylating or crosslinking a complex consisting of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent, and a process for the production thereof. The nonaqueous solvent used in the invention is preferably one or more solvents selected from the group consisting of chloroform, toluene, methylene chloride and heptane.

A porous lithium manganese phosphate-carbon composite material, and a preparation and application thereof. Multiple nano-pores are distributed in the composite material, and the composite material includes a lithium manganese phosphate material and carbon. The method for preparing the porous lithium manganese phosphate-carbon composite material includes the steps of: mixing a porous pyrophosphate material with a doped metal source, a lithium source, phosphate and a carbon source and then drying them to obtain a reaction precursor, and calcining the reaction precursor at a constant temperature under a protective atmosphere to obtain the composite material. The lithium manganese phosphate material contains compounds in a general formula of LiMn_xM_1−xPO₄, and the porous pyrophosphate material contains compounds in a general formula of (Mn_xM_1−x)₂P₂O₇ and 0 wt % to 50 wt % of carbon, where M comprises a transition metal, and 0.6≦x≦1.

The present invention provides an apparatus for processing organic substances, by which performance of processing the organic substances is enhanced. The present invention includes a grinding device for grinding inputted organic substances and a drying device for drying the organic substances grinded by the grinding device.

Provided is an antibacterial aqueous solution comprising a phosphate, a citrate, and a silicate; a method of controlling bacterial contamination and/or growth in food substance; a method of prohibiting the formation of, and/or facilitating the removing of, silicate aggregation on metal article; and a method of reducing phosphate usage in industrial antibacterial process.

A liquid crystal display includes a light guide plate guiding light, light sources disposed adjacent to at least one side of the light guide plate, and a lower receptacle. The lower receptacle includes a bottom plate on which the light guide plate and the light sources are disposed, a lower receptacle side wall extending in a direction substantially perpendicular to the bottom plate and from an edge of the bottom plate, and an upper plate extended from the lower receptacle side wall and substantially parallel to the bottom plate. The upper plate does not overlap the light guide plate in a plan view of the liquid crystal display.

A composition for oral administration includes: a water-insolubilized material including a bitter or astringent substance, such as an iso-α acid, and a polyvalent metal salt such as ferric chloride; and a dispersant such as a water-soluble macromolecule such as gelatin or gum arabic.

A device for storing and dispensing a substance includes a container having a body defining therein a storage chamber for receiving and storing the substance. The container includes a first passageway that is in fluid communication with the storage chamber of the body and defines a flow path therebetween. The container also includes a pierceable wall located on an opposite side of the first passageway relative to the storage chamber, and a first threaded connecting portion located at one end of the body for connecting another component thereto. The device also includes a one-way valve assembly that includes a valve body including a body base defining a second passageway and a piercing portion mounted within the valve body and engageable with the pierceable wall of the container. At least one of the piercing portion and the pierceable wall is movable relative to the other between a first position wherein the pierceable portion is not piercing the pierceable wall, and a second position wherein the pierceable portion is piercing the pierceable wall and the first passageway of the container is in fluid communication with the second passageway of the valve body for allowing the flow of substance from the storage chamber therethrough. The valve assembly includes a second threaded connecting portion that is threadedly connectable to the first threaded connecting portion of the container for fixedly securing the valve assembly to the container when the valve assembly and container are located in the second position. A manually-engageable and removable member is disposed intermediate the valve body and the container that prevents movement of at least one of the piercing portion and pierceable wall to the second position until the removable member is removed. The valve assembly includes a valve seat and at least one flow aperture extending through the valve body adjacent to the valve seat and in fluid communication with the second passageway for receiving the substance from the storage chamber there through.

In a method for obtaining dinitrogen monoxide by microbiological or enzymatic processes from nitrogen-containing substances, the microorganisms, bacteria, archaea, eukaryotes, fungi, parasites, phages, cells, cell fractions or membrane fractions, and/or enzymes, and/or a combination thereof to be used in this context are selected, or manipulated or partly or entirely reversibly and/or irreversibly inhibited by suitable actions, or the corresponding microbiological or enzymatic processes are controlled, for example, by way of suitable process conditions, so that, in part or entirely, dinitrogen monoxide (N₂O) is formed from the nitrogen-containing compounds of the nitrogen-containing substances.

The present invention provides an apparatus for processing organic substances such as food and the like, by which time and costs for processing the organic substances are reduced to enhance performance of processing the organic substances. The present invention includes a dewatering means for separating moisture from inputted inorganic substances and a drying means provided to one side of the dewatering means for drying the inorganic substances discharged from the dewatering means.

The invention discloses an injection medicine composition for improving the stability of a quercetin medicine injection preparation, and a preparation method thereof. The injection medicine composition is an injection medicine composition mainly prepared by dissolving salt of quercetin into injection water and adding citric acid and/or sodium citrate as pH regulators to regulate the pH value of medicine liquid. The consumption of the citric acid and/or sodium citrate is 0.1mg to 200.0mg/100ml. The injection medicine composition has the advantages that the pH value of the injection liquid is more stable; the quercetin degradation substances are greatly reduced through being compared with that in the prior art; under the condition of not using other solutizers increasing the clinic application risks, the clarity of the quercetin injection liquid is improved; the problems of small white points, white blocks and solution turbidity of a product of the quercetin injection liquid in the prior art under the condition of long storage time are particularly solved; the visible foreign matter inspection of the product is enabled to conform to the specification of the medicine quality standard; the clinic medication and popularization are convenient.

The invention discloses an injecting medicine composition for improving the stability of a ginsenoside medicine injection and a preparation method thereof. The preparation method mainly comprises the following steps: dissolving salt of ginsenoside in injecting water; adding citric acid and/or sodium citrate to serve as a pH regulator, and regulating the pH value of the medicinal liquid, wherein the dosage of the citric acid and/or sodium citrate is 0.1-200.0mg/100ml. By adopting the preparation method, the pH value of the injection can be stable, the ginsenoside degraded substances are greatly reduced in comparison with that in the prior art, the clarity of ginsenoside injection is improved under a condition that other cosolvent capable of increasing clinical application risks is prevented from being used, and the problems that the ginsenoside injection has small spots, white blocks and turbid solution by adopting the prior art under a condition of long storage period can be especially solved, obviously foreign matter inspection of the injection accords with the specification of medicine quality standard, and clinical medication and popularization can be benefited.

A practical technique that enables effective utilization of organic wastes is provided. In order to achieve the above-mentioned object, a method for producing methane gas from organic wastes according to the present invention includes: treating organic wastes with at least one of supercritical water and sub-critical water to convert the organic wastes into low molecular weight substances; and subjecting the low molecular weight substances to methane fermentation. According to the method, initially, the organic wastes are treated with at least one of the supercritical water and the sub-critical water so as to be converted into low molecular weight substances that are easily subjected to methane fermentation. Then, the treated substances are subjected to methane fermentation. Consequently, methane gas can be produced from the organic wastes at a high speed with high digestion efficiency.

The invention discloses a pharmaceutical composition for injection for improving stability of an illicium henryi medication injection preparation. The pharmaceutical composition for injection is mainly prepared by dissolving extracting solution of illicium henryi in water for injection, adding caffeic acid and/or sodium caffeate to serve as a pH regulator for regulating the pH value of the liquid medicine, wherein the amount of the caffeic acid and/or sodium caffeate is 1-5g/100ml. According to the invention, the pH value of the injection can be stable, illicium henryi degradable substances are greatly reduced compared with that in the prior art, the clarity of the illicium henryi injection is improved under the condition that other cosolvents capable of increasing clinical application risk are not used, particularly the problems that the illicium henryi injection has small white spots and white blocks and turbid in solution when stored for a long time by adopting the products in the prior art are solved, inspection of visible foreign matters in the product can accord with regulations of drug standards, and the pharmaceutical composition is convenient for clinical medication and popularization.

The invention discloses an injection medicinal composition of houttuyfonate. The injection medicinal composition is mainly prepared by the steps of dissolving salt of houttuyfonate in injection water,and adding citric acid and/or sodium citrate to serve as a pH regulator to adjust the pH value of medicinal liquid, wherein the dose of the citric acid and/or sodium citrate is 0.1-200.0mg/100ml. According to the injection medicinal composition, the pH value of injection can be more stable, the houttuyfonate recalcitrant substance is greatly reduced in comparison with that in the prior art, the clarity of a houttuyfonate injection can be improved under the condition that other co-solvent increasing clinical application risk is prevented from being used, the problems of small white dots, whiteblocks and solution turbidity occurring in the houttuyfonate injection can be solved when the product is stored for a relatively long time by adopting the prior art, the condition that the visible foreign inspection of a product can accord with the specification of drug standard can be guaranteed, and clinical administration and popularization can be facilitated.

The invention discloses an injection pharmaceutical composition for improving stability of a rhizoma dioscoreae nipponicae drug injection preparation. The injection pharmaceutical composition is mainly prepared by dissolving an extracting solution of rhizoma dioscoreae nipponicae in water, and regulating pH value of medicine liquid with the addition of formic acid and/or sodium formate which serves as a pH regulator, wherein the dosage of the formic acid and/or the sodium formate is 1-3g/100ml. According to the injection pharmaceutical composition disclosed by the invention, the stability of the pH value of the injection (the injection pharmaceutical composition) is enhanced, the content of rhizoma dioscoreae nipponicae degradable substances is greatly reduced in comparison with the prior art, and the clarity of the rhizoma dioscoreae nipponicae injection is improved under the circumstance of avoiding the use of other cosolvents which can increase the risk of clinical application; especially, the problems of the prior art that small white spots, white plaques and solution turbidity easily occur in a finished rhizoma dioscoreae nipponicae injection product can be solved; the obvious foreign matter inspection of the product (the injection pharmaceutical composition) can conform to the specifications of drug quality standard; and the injection pharmaceutical composition is convenient for clinical medication and popularization.

The invention discloses a medicinal composition for injection, used for improving the stability of a silymarin medicine injection preparation. The medicinal composition for injection is prepared through the following steps: dissolving a silymarin salt in injection water, and adding citric acid and/or sodium citrate used as a pH regulator to regulate the pH value of the obtained medicinal solution, and the use amount of citric acid and/or sodium citrate is 0.1-200.0mg/100ml. The medicinal composition for injection makes the pH value of injections be stable, greatly reduces silymarin degrading substances, improves the clearness of silymarin injections without using other cosolvents increasing clinic application risks, especially solves the problems of small white spots, white blocks and solution turbidity of present silymarin injections in the prior art after long-time storage, can guarantee that the visible foreign matter inspection process of the product accords with medicine quality standard prescriptions, and can be conveniently and clinically used and promoted.